Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

NCT03090659 is registered in ClinicalTrials.gov with Nanjing Legend Biotech Co. as lead sponsor.

NCT NCT03090659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03090659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients
Lead sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 2, 2015
Completion date
December 31, 2023
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or relapsed multiple myeloma